This study is the first to describe age-related changes in a large cohort of patients with Phelan-McDermid syndrome (PMS), also known as 22q13 deletion syndrome. Over a follow-up period of up to 12 years, physical examinations and structured interviews were conducted for 201 individuals diagnosed with PMS, 120 patients had a focused, high-resolution 22q12q13 array CGH, and 92 patients' deletions were assessed for parent-of-origin. 22q13 genomic anomalies include terminal deletions of 22q13 (89 %), terminal deletions and interstitial duplications (9 %), and interstitial deletions (2 %). Considering different age groups, in older patients, behavioral problems tended to subside, developmental abilities improved, and some features such as large or fleshy hands, full or puffy eyelids, hypotonia, lax ligaments, and hyperextensible joints were less frequent. However, the proportion reporting an autism spectrum disorder, seizures, and cellulitis, or presenting with lymphedema or abnormal reflexes increased with age. Some neurologic and dysmorphic features such as speech and developmental delay and macrocephaly correlated with deletion size. Deletion sizes in more recently diagnosed patients tend to be smaller than those diagnosed a decade earlier. Seventy-three percent of de novo deletions were of paternal origin. Seizures were reported three times more often among patients with a de novo deletion of the maternal rather than paternal chromosome 22. This analysis improves the understanding of the clinical presentation and natural history of PMS and can serve as a reference for the prevalence of clinical features in the syndrome.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00439-014-1423-7DOI Listing

Publication Analysis

Top Keywords

patients phelan-mcdermid
8
phelan-mcdermid syndrome
8
terminal deletions
8
patients
6
deletions
5
clinical genomic
4
genomic evaluation
4
evaluation 201
4
201 patients
4
syndrome
4

Similar Publications

Phelan-McDermid syndrome-associated psychosis: a systematic review.

Acta Neuropsychiatr

November 2024

Department of Psychiatry, Hotchkiss Brain Institute, Mathison Centre for Mental Health Research and Education, University of Calgary, Calgary, AB, Canada.

Article Synopsis
  • Phelan-McDermid syndrome is a rare genetic disorder with various neurodevelopmental and psychiatric issues, with psychosis being less commonly reported but still significant.
  • A systematic review gathered data from 18 English-language articles on 35 individuals to examine psychosis characteristics, its association with other symptoms, and responses to antipsychotic treatments.
  • Findings suggest psychosis typically starts around age 17, with many also experiencing catatonia and mood symptoms; while antipsychotic treatments showed some effectiveness, more high-quality research is needed to guide treatment options.
View Article and Find Full Text PDF

Phelan-McDermid syndrome (PMS) is a neurodevelopmental disorder characterized by a developmental delay and autism spectrum disorder (ASD)-like behaviors. Emerging research suggests a link between gut microbiota and neuropsychiatric conditions, including PMS. This study aimed to investigate the fecal microbiota and immune profiles of children with PMS compared to healthy controls.

View Article and Find Full Text PDF

Background: Phelan-McDermid syndrome (PMS) is caused by monoallelic loss or inactivation at the SHANK3 gene, located in human chr 22q13.33, and is often associated with Autism Spectrum Disorder (ASD).

Objectives: To assess the clinical and developmental phenotype in a novel sample of PMS patients, including for the first time auxometric trajectories and serotonin blood levels.

View Article and Find Full Text PDF
Article Synopsis
  • Phelan-McDermid syndrome (PMS) is a rare neurodevelopmental disorder linked to deletions of the 22q13 region, particularly affecting the SHANK3 gene, leading to various developmental challenges like intellectual disabilities and autism.
  • Researchers conducted a study using the PMS International Registry to analyze clinical and genetic data from 401 individuals to understand how the size of deletions affects their clinical features.
  • Findings revealed that larger deletions were associated with more severe developmental delays and physical issues, while individuals with smaller deletions or specific SHANK3 variants tended to show better self-help and verbal skills along with various psychiatric diagnoses.
View Article and Find Full Text PDF

On September 27, 2023, the CureSHANK nonprofit foundation sponsored a conference in Boston, Massachusetts, to identify gaps in knowledge surrounding SHANK3-related epilepsy with the goal of determining future research priorities and recommendations. In addition to patient families and members of the CureSHANK community, participants in the conference included a broad cross-section of preclinical and clinical researchers and clinicians with expertise in SHANK3-related epilepsy as well as representatives from the pharmaceutical industry. Here we summarize the outcomes from comprehensive premeeting deliberations and the final conference recommendations, including (1) gaps in knowledge related to clinical science, (2) gaps in knowledge related to preclinical science, and (3) research priorities moving forward.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!